Focus Investment Banking

JUNE 13, 2023

As we’ve seen in other healthcare verticals, PE interest is driven by the opportunity to provide growth capital, contribute management expertise, and consolidate a fragmented industry to increase efficiency. In addition to negotiated payments, providers can earn incentives for providing high-quality, efficient care.

Hospitality 52

Hospitality Private Equity Medical Mergers and Acquisitions 52

Cooley M&A

OCTOBER 29, 2020

Unlike prior iterations of SPAC activity and perhaps unsurprising given the increasing number of SPAC IPOs, the panelists noted that companies considering going public by way of a SPAC are often negotiating with multiple SPAC sponsors in the preliminary phase of a potential transaction. Revisiting Governance Documentation.

M&A 52

M&A IPO Valuation Mergers and Acquisitions 52

Cooley M&A

JANUARY 25, 2023

Novartis announced plans to spin off its generics and biosimilars division into a publicly traded stand-alone company. 2022 was the busiest year for activism in the past four years, and the healthcare and life sciences industry was no exception.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 20, 2022

For example, early in 2021, Zimmer Biomet Holdings announced that it would spin off its spine and dental businesses into a new publicly traded company as a way to “optimize resource allocation” among its remaining businesses. Of the 20 largest public deals in the healthcare sector in 2021, 14 featured all?cash

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Cooley M&A

JANUARY 25, 2023

The rules are expected to increase the frequency of proxy contests (particularly by less-established activists), afford dissidents increased leverage in settlement negotiations, and increase focus on the strength and qualifications of individual directors.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Cooley M&A

JANUARY 22, 2025

Public company deals: Smaller bites in more focused therapeutic areas The landscape for public company sales in the life sciences sector in 2024 was notably quieter than expected, with anticipated high-profile deals failing to materialize. 2] Novo Holdings $16.5

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64